Cytodyn Inc (CYDY)

[trding]

Still in animal trials, maybe the missing ingredient is Pro 140, allowing GS 9260 to drive infected cells out of the body with both Pro 140 and PGT 121 stopping news ones being created. After Gilead purchases Pro 140, maybe they will try that combination.

While it's still early, the combination appears to be the closest thing we've got to a drug cure at the moment. GS-9620 is currently being tested in a phase 1b trial in HIV patients taking ART. And Gilead has a derivative of PGT121 called GS-9722 that's in phase 1 testing. Presumably, Gilead plans to test the combination in humans eventually, although it hasn't released a timeline yet.

ART treatments work pretty well, allowing patients to live decades without the viral infection progressing to AIDS. Unfortunately ART treatments have some side effects, which are exacerbated by the fact they have to be taken for the rest of patients' lives.

Even if a combination of GS-9620 and GS-9722 isn't a complete cure, it could allow patients to take a break from ART, reducing the lifetime exposure to side effects. It would also eliminate the daily burden of taking the medication, which can lead to development of resistant versions of the virus if medication adherence isn't high.